Biovica, a Swedish biotech company founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies, has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum TKa assay in Italy.
In Italy, some 17,000 women are diagnosed with metastatic breast cancer every year. IT Health Fusion, which is a subsidiary of the biotech and pharmaceutical company BIOVIIIx, will lead the Italian market introduction, where the initial focus will be on private insurance and out-of-pocket markets, together constituting some 40 per cent of the Italian market.
